Physicochemical Properties
| Molecular Formula | C17H32NO9P |
| Molecular Weight | 425.411046981812 |
| Exact Mass | 423.165 |
| CAS # | 2004714-34-3 |
| Related CAS # | Hex;2004714-32-1 |
| PubChem CID | 122540908 |
| Appearance | White to light yellow solid powder |
| LogP | 1.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 11 |
| Heavy Atom Count | 28 |
| Complexity | 600 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C1CCN(O)C(C1P(=O)(OCOC(C(C)(C)C)=O)OCOC(O)C(C)(C)C)=O |
| InChi Key | TVFIFFUSHZDTKT-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C17H30NO9P/c1-16(2,3)14(20)24-10-26-28(23,12-8-7-9-18(22)13(12)19)27-11-25-15(21)17(4,5)6/h12,22H,7-11H2,1-6H3 |
| Chemical Name | [2,2-dimethylpropanoyloxymethoxy-(1-hydroxy-2-oxopiperidin-3-yl)phosphoryl]oxymethyl 2,2-dimethylpropanoate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | POMHEx (78 nM, 8h) significantly affects ENO1-deficient cells but has no impact on ENO1-WT glioma cells [1]. POMHEx (0-720 nM) specifically causes energy stress, suppresses growth, and initiates death in glioma cells lacking ENO1 [1]. |
| ln Vivo | Hemolytic anemia was consistently avoided with POMHEx (iv, ip) injections at doses up to 10 mg/kg (body weight) per day. POMHEx (intravenous, 35 mg/kg) makes patients drowsy, which leads vets to start the euthanasia process [1]. In isolated mouse plasma, POMHEX hydrolyzes quickly to Hemi POMHEX, which has a half-life of roughly 30 seconds, while in isolated human blood, it has a half-life of almost 9 minutes [1]. |
| Cell Assay |
Cell Proliferation Assay[1] Cell Types: ENO1-deleted (D423, red), ENO1-isogenically rescued (D423 ENO1, blue) and ENO1-WT (LN319, gray) cells. Tested Concentrations: 78 nM. Incubation Duration: 8 h. Experimental Results: Down-regulated cell density. |
| References |
[1]. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab. 2020 Nov 23. |
Solubility Data
| Solubility (In Vitro) | DMSO : 100 mg/mL (236.18 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (5.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3507 mL | 11.7534 mL | 23.5067 mL | |
| 5 mM | 0.4701 mL | 2.3507 mL | 4.7013 mL | |
| 10 mM | 0.2351 mL | 1.1753 mL | 2.3507 mL |